Purpose
Considering the clear emerging role of the DNA repair and the cell cycle checkpoints as predictive, prognostic and therapeutic targets in cancer there is a need to better characterized human tumours to define sub-sets of patients that would benefit of a particular treatment modality. The aim of the present work is to characterize molecularly a cohort of Triple Negative Breast Cancers (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by immunohistochemistry) compared to Luminal A Breast Cancer (LABC; estrogen receptor positive and/or progesterone receptor positive, and HER2/neu negative, ki67 expression < 15% by immunohistochemistry) as regard of gene expression involved in DNA repair pathway (in particular genes involved in nucleotide excision repair, base excision repair, homologous recombination repair and BRCA/Fanconi anemia pathway) and cell cycle checkpoint pathway (CHK1) and their correlation with the clinical-pathological characteristics. 
Experimental design

Results
Among the NER genes, ERCC1 (p < 0.0001) and XPA (p = 0.03) genes were significantly less expressed in TNBC than in LABC; among the FA genes, BRCA1 (p < 0.0001), FANCD2 (p < 0.0001), FANCF (p < 0.0001) and PALB2 (p = 0.0006) genes were significantly less expressed in TNBC than in LABC. Also CHK1 was less expressed in TNBC (p < 0.0001).
In relation to the clinical-pathological characteristics, lower level of XPG and FANCA were associated with larger tumor size (≥ pT2) at definitive surgery in TNBC.
The high expression of FANCA was related to an increase of either the Overall Survival (p = 0.0045) or the Event-Free Survival (p = 0.0141) on univariate analysis in TNBC.
Conclusions
DNA repair and cell cycle checkpoint related genes with particular regards to ERCC1/XPA in NER family, BRCA/FANC family and CHK1 may be useful as prognostic markers in TNBC and likely to be important in 
